Ticker IRLAB-AListed on Nasdaq Stockholm
IRLAB Therapeutics AB
At a glance
Most recent filing on July 9, 2026 — an open-market purchase by James Gamgort on Jul 8, 2026.
Over the past 12 months: 3 open-market purchases and 0 open-market sales.
We hold 43 visible filings, going back to July 10, 2019.
Filings we could not classify with confidence are set aside for review, so they are in none of these counts.
Insider trades
What is a MAR filing?5 of 43 shown
- James Gamgort Board member$1,470Open-market buy
- James Gamgort Board member$30,000Open-market buy
- Joakim Tedroff Closely associated: Other member of the administrative, management or supervisory body140,000 SEKOpen-market buy
- Joakim Tedroff Closely associated: Other member of the administrative, management or supervisory body120,000 SEKOpen-market buy
- Kristina Torfgård Chief executive officer140,850 SEKOpen-market buy
Short positions
All short positionsNet short positions of 0.5% or more in IRLAB Therapeutics AB that are open today, as the regulator publishes them. Together they come to 0.79% of the shares. Positions below 0.5% are not published, so the real total can be higher.
1 open position, together 0.79%. The holders and their history are part of the subscription.
Källa: Finansinspektionen, November 16, 2026.